Successful treatment with repeated dexamethasone implant injections for recurrent macular edema after acute retinal necrosis

Ragnhild Øvstebø Sørland1*, Anne Kjersti Erichsen1, Thora Elisabet Jonsdottir1, Marius Nordberg Bromnes1, Peter Mæhre Lauritzen2 and Jon Roger Eidet1

Abstract

Background: The treatment of recurrent cystoid macular edema associated with acute retinal necrosis is challenging due to the concern that treatment with intravitreal steroids may reactivate the retinitis.

Case report: An immunocompetent patient diagnosed with acute retinal necrosis was treated with oral valacyclovir and intravitreal injections of foscarnet. Giant tears in her retina necessitated a vitrectomy with silicone oil. She developed cystoid macular edema after the removal of the silicone oil. The edema responded to high-dose prednisolone but recurred when the dose was tapered to 20 mg daily. Under close surveillance and increased antiviral medication, she was treated with a dexamethasone implant with complete resolution of the edema. Unfortunately, the edema recurred, and the treatment had to be repeated. Over 18 months, she received five dexamethasone implants without recurrence of the viral retinitis.

Conclusions: This case shows successful treatment of recurring cystoid macular edema following acute retinal necrosis with repeated intravitreal dexamethasone implants in a patient receiving valacyclovir maintenance treatment.

Keywords: Acute retinal necrosis, Cystoid macular edema, Dexamethasone implant, Valacyclovir

Introduction

Acute retinal necrosis (ARN) is a rare and potentially blinding disease [9]. Cystoid macular edema (CME) is one of many complications causing poor visual outcomes in ARN patients [11], and the most common cause of permanent visual loss among uveitis patients [2, 7]. The treatment of CME in uveitis patients can be challenging because the edema often recurs [1]. Corticosteroids are the mainstay in treating non-infectious uveitic CME [1]. However, in the case of infectious uveitis, caution should be taken. There is no consensus about the treatment of CME secondary to ARN, nor is there any consensus on the dosage of antiviral medications when patients are treated with intravitreal steroids.

Case report

An immunocompetent woman in her early twenties was referred to The Department of Ophthalmology in Oslo with a painful left eye and reduced vision. Her best-corrected visual acuity (BCVA) was 20/100 (Snellen equivalent), and a slit-lamp examination revealed 3+ cells in the anterior chamber and vitritis. Fundus examination showed inflammatory optic disc edema and peripheral confluent areas of a necrotic retina (Fig. 1). There was no pathology in her right eye. Vitreous sampling for polymerase chain reaction (PCR) analysis confirmed the presence of DNA from the herpes simplex virus type 2 (HSV-2). She was diagnosed with acute retinal necrosis,

*Correspondence: ragsoe@ous-hf.no
1 Department of Ophthalmology, Oslo University Hospital, Oslo, Norway
Full list of author information is available at the end of the article
and oral induction therapy with valacyclovir 2 g four times daily was initiated. She received four intravitreal injections of 2.4 mg foscarnet in 0.1 ml during the first nine days of admission. Due to the optic disc edema, she was started on oral prednisolone at 40 mg daily, which was gradually tapered and discontinued after three months.

Giant tears in the necrotic retina complicated the initial diagnostic vitrectomy. This necessitated a second vitrectomy two weeks later with silicone oil and prophylactic laser retinopexy and cryopexy. Her BCVA after surgery was 20/30, and optical coherence tomography (OCT) showed no sign of macular edema. After removal of the silicone oil five months after the second vitrectomy, she developed increased inflammation in the anterior chamber and CME. The CME responded to oral prednisolone at 60 mg daily but recurred when tapering the dose to 20 mg daily. Even though a minor CME remained, prednisolone was discontinued to avoid oral steroid-related adverse effects.

Within the first year, valacyclovir was slowly tapered to a maintenance dose of 500 mg three times daily. Eighteen months after the first admission she had developed a mature cataract that required surgery. While still on valacyclovir 500 mg three times daily, prednisolone 60 mg daily was reintroduced pre-operatively to control inflammation. Postoperatively there was no CME, and her BCVA was 20/30. The CME recurred when prednisolone was tapered to 20 mg daily, and her BCVA declined to 20/100, both due to CME and the development of posterior capsular opacification (PCO). She then received one intravitreal injection of 0.05 ml aflibercept with no apparent effect on the CME.

As the treatment of the CME necessitated unacceptably high doses of oral prednisolone, and the edema was unresponsive to injection with aflibercept, intravitreal steroid injections were initiated. The valacyclovir maintenance dose was doubled to 1 g three times daily before injecting intravitreal triamcinolone 4 mg in 0.1 ml. One week after the injection, there was an improvement in the CME. However, the BCVA was still 20/100 due to PCO, and a YAG capsulotomy was performed. Two months later, the CME was worsening (Fig. 2), and while still on valacyclovir 1 g three times daily, an intravitreal 700 ug dexamethasone implant was injected. Four weeks later, there was a complete resolution of the CME (Fig. 3), and her BCVA had improved to 20/50. Two months after the first dexamethasone implant, valacyclovir maintenance therapy was reduced to 500 mg three times daily.

The patient received five dexamethasone implants over 18 months while maintaining her BCVA level at 20/40. The injection interval was between 12 and 18 weeks. She was monitored closely with regular fundus exams and intraocular pressure measurements. There was no sign of reactivation of retinitis.
Discussion
Acute retinal necrosis is an infectious retinitis caused by members of the herpes virus family [6]. In the absence of antiviral medication, corticosteroids should be used cautiously as this may promote viral replication [8, 10]. Although oral corticosteroids are routinely used to treat acute inflammation and optic disc edema in ARN patients [11], there is concern that steroids may reactivate the retinitis when injected intravitreally.

Macular edema will cause permanent damage to the anatomic structures in the macula and irreversible visual loss if left untreated. Our patient had a BCVA level of 20/30 when her macular edema was treated with high-dose prednisolone. Unfortunately, long-term use of systemic corticosteroids may have serious adverse effects [1], so an alternative treatment modality was needed. Vascular endothelial growth factor inhibitors have been tried in non-infectious uveitic macular edema with variable results [3, 5]. Ortega-Evangelio et al. [5] reported a case of CME secondary to ARN successfully treated with intravitreal aflibercept. However, aflibercept did not improve the CME in our patient. Majumder et al. 2016 [4] reported two cases of CME in ARN patients, in one of which PCR confirmed the varicella-zoster virus. The CME in each case was successfully treated with two dexamethasone implant injections three months apart while using valaciclovir 1 g three times daily. In contrast, our patient had ARN due to HSV-2, and her CME was successfully treated with five dexamethasone implant injections over 18 months. In addition, the retinitis did not reactivate in our patient even though she used a lower valaciclovir maintenance dosage than reported by Majumder et al.

In this patient, repeated intravitreal dexamethasone implants with concomitant valacyclovir maintenance treatment proved to be an effective long-term treatment for CME secondary to ARN.

Abbreviations
ARN: Acute retinal necrosis; CME: Cystoid macular edema; BCVA: Best corrected visual acuity; PCR: Polymerase chain reaction; HSV-2: Herpes simplex virus type 2; OCT: Optical coherence tomography; PCO: Posterior capsular opacification.

Acknowledgements
None.

Authors’ contributions
All authors wrote and reviewed the main manuscript and the authors read and approved the final manuscript. R.O.S. and J.R.E. prepared Figs. 1, 2 and 3.

Funding
The authors received no funding. It is the authors' own work, not funded by government or academic institutions.

Availability of data and materials
Not applicable.

Declarations

Ethics approval and consent to participate
The study adhered to the tenets of the Declaration of Helsinki. Approval has been obtained from the Institutional Data Protection Officer at Oslo University Hospital. As this is a case report it does not require approval by a research ethics committee.

Consent for publication
The patient has consented to publication.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Ophthalmology, Oslo University Hospital, Oslo, Norway. 2 Department of Radiology, Oslo University Hospital, Oslo, Norway.

Received: 22 August 2022 Accepted: 5 October 2022
Published online: 21 October 2022

References
1. Koronis S, Stavarakas P, Balidis M, Kozeis N, Tranos PG (2019) Update in treatment of uveitic macular edema. Drug Des Devel Ther 13:667–680. https://doi.org/10.2147/DDDT.S166092
2. Lardenoye CW, van Kooij B, Rothova A (2006) Impact of macular edema on visual acuity in uveitis. Ophthalmology 113(8):1446–1449. https://doi.org/10.1016/j.jophtha.200603.027
3. Mackensen F, Heinz C, Becker MD, Heiligenhaus A (2008) Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina 28(1):41–45. https://doi.org/10.1097/IAE.0b013e318156db75
4. Majumder PD, Biswas J, Ambreen A, Amin R, Pannu ZR, Bedda AM (2016) Intravitreal dexamethasone implant for the treatment of cystoid macular oedema associated with acute retinal necrosis. J Ophthalmic Inflamm Infect 6(1):49. https://doi.org/10.1186/s12348-016-0116-x
5. Ortega-Evangelio L, Navarrete-Sanchis J, Williams BK, Tomas-Torrent JM (2018) Aflibercept in the management of acute retinitis syndrome-related macular edema. Eur J Ophthalmol 28(2):259–261. https://doi.org/10.5301/ejo.5001039
6. Powell B, Wang D, Llopart S, Rosen RB (2020) Management strategies of acute retinal necrosis: current perspectives. Clin Ophthalmol 14:1931–1943. https://doi.org/10.2147/CPT2.528488
7. Rothova A, Suttorp-van Schulten MS, Frits Trefers W, Klijstra A (1996) Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 80(4):332–336. https://doi.org/10.1136/bjo.80.4.332
8. Satoh N, Abe T, Nakajima A, Sakurai S (1998) Recurrent varicella-zoster virus retinitis in a patient treated with systemic corticosteroids. Ocul Immunol Inflamm 6(3):185–188. https://doi.org/10.1080/612348.016-0116-4
9. Tam PM, Hooper CY, Lightman S (2010) Antiviral selection in the management of acute retinal necrosis. Clin Ophthalmol 4:11–20
10. Weissman HM, Biousse V, Schechter MC, Del Rio C, Yeh S (2015) Bilateral central retinal artery occlusion associated with herpes simplex virus-associated acute retinal necrosis and meningitis: case report and literature review. Ophthalmic Surg Lasers Imaging Retina 46(2):279–283. https://doi.org/10.3928/23258160-20150213-24
11. Wong RW, Jumper JM, McDonald HR, Johnson RN, Fu A, Luan BJ, Cunningham ET Jr (2013) Emerging concepts in the management of acute retinal necrosis. Br J Ophthalmol 97(5):545–552. https://doi.org/10.1136/bjophthalmol-2012-030193

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.